-transparent.png){kind=logo}
Methylated Digoxin preparation--beta-Methyldigoxin (Lanitop) was used in 50 patients with congestive heart failure of different etiology (tablets of 0.3--0.6 mG per day). Its employment proved very effective in the treatment of congestive heart failure. It is not contraindicated to patients with chronic coronary insufficiency with underlying athrosclerotic cardiosclerosis with signs of congestive circulatory insufficiency. Side-effects of beta-Methyldigoxin are mild and noted rather seldom.
Related Publications
B Ia Bart, and
M N Biriukova, and
P M Savenkov, and
I A Rumiantseva
August 1974,
Polski tygodnik lekarski (Warsaw, Poland : 1960),
B Ia Bart, and
M N Biriukova, and
P M Savenkov, and
I A Rumiantseva
January 1974,
Padiatrie und Padologie,
B Ia Bart, and
M N Biriukova, and
P M Savenkov, and
I A Rumiantseva
October 1989,
Kardiologiia,
B Ia Bart, and
M N Biriukova, and
P M Savenkov, and
I A Rumiantseva
January 1992,
European journal of clinical pharmacology,
B Ia Bart, and
M N Biriukova, and
P M Savenkov, and
I A Rumiantseva
September 1975,
Japanese heart journal,
B Ia Bart, and
M N Biriukova, and
P M Savenkov, and
I A Rumiantseva
August 1975,
Wiener medizinische Wochenschrift (1946),
B Ia Bart, and
M N Biriukova, and
P M Savenkov, and
I A Rumiantseva
January 1980,
Japanese heart journal,
B Ia Bart, and
M N Biriukova, and
P M Savenkov, and
I A Rumiantseva
April 1999,
The Journal of family practice,
B Ia Bart, and
M N Biriukova, and
P M Savenkov, and
I A Rumiantseva
January 1977,
Verhandlungen der Deutschen Gesellschaft fur Kreislaufforschung,
B Ia Bart, and
M N Biriukova, and
P M Savenkov, and
I A Rumiantseva
September 2016,
Annales de cardiologie et d'angeiologie,
